Total
0
Shares
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow
MD and CEO, Matthew Liddelow
Source: NeuroScientific Biopharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NeuroScientific Biopharmaceuticals (NSB) is partnering with Linear Clinical Research to begin Phase 1 clinical trials with its lead drug candidate EmtinB
  • This marks the first in-human study of EmtinB in up to 90 healthy volunteers, with the trial seeking to assess the drug’s safety and tolerability
  • The company says the study will be used to support future Phase II trials in Alzheimer’s disease and multiple sclerosis
  • NeuroScientific Biopharmaceuticals last traded at 36 cents on June 22

NeuroScientific Biopharmaceuticals (NSB) has partnered with Linear Clinical Research to begin Phase 1 clinical trials with its lead drug candidate EmtinB.

EmtinB is a compound that binds to surface-based cell receptors, stimulating neuroprotection, neuroregeneration and modulate neuroinflammation. The company says the treatment is safe and well tolerated at high concentrations and is able to penetrate the blood brain barrier.

Perth-based clinical research organisation, Linear, will assist with the first in-human study of EmtinB in healthy volunteers, with the trial seeking to assess the drug’s safety, tolerability and pharmacokinetics.  

Up to 90 participants are set to be recruited, with multiple dose cohorts utilised. The study will then be used to support future Phase II trials in Alzheimer’s disease and multiple sclerosis.

“This partnership is a significant milestone for NeuroScientific and we are elated to be transitioning our R&D (research and development) program into first-in-human trials with another leading-edge, WA-based company in Linear Clinical Research,” NSB’s Managing Director, Matt Liddelow said.

“The trial is also a significant milestone for the advancement of EmtinB as a potential disease-modifying drug for a range of neurodegenerative conditions that currently lack such treatments, including Alzheimer’s disease and Multiple sclerosis.”

Additionally, NSB plans to undertake a Phase I trial of EmtinB in glaucoma patient, with the treatment administered by intravitreal delivery.

NeuroScientific Biopharmaceuticals last traded at 36 cents on June 22.


NSB by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.